Long Non-Coding RNA TMPO-AS1 Promotes Malignant Behaviors of Hepatocellular Carcinoma Cells via YWHAG/ERK Pathway DOI
Xiaoxiao Xie, Le Qin, Fenglei Dong

et al.

Science of Advanced Materials, Journal Year: 2023, Volume and Issue: 15(3), P. 349 - 360

Published: March 1, 2023

Increasing attention has been paid to long noncoding RNAs (lncRNAs) as they have implicated in the tumorigenesis of many malignancies, such hepatocellular carcinoma (HCC). The current research explored pro-tumorigenic biological function lncRNA, TMPO-AS1, HCC, and uncovered underlying mechanism. correlations between TMPO-AS1 expression clinical outcome HCC were analyzed based on GEO KM plotter databases. differential normal liver tissues/cells was by real-time quantitative PCR. HepG2 Huh7 cell lines exploited this study. protein levels Western blot. Cell viability determined CCK-8 colony formation experiments; while migration invasion capacities observed wound healing Transwell, respectively. RNA pulldown RIP assay adopted determine interaction YWHAG. tissues significantly higher than that tissues, positively correlated with tumor grade poor prognosis patients. ERK signaling pathway could be activated overexpressing but repressed silencing cells. Mechanically, directly interacted YWHAG up-regulated its inhibiting ubiquitination. effects causing overexpression silence proliferation, migration, invasion, EMT process cells blocked overexpression, may facilitate malignant behaviors YWHAG/ERK pathway.

Language: Английский

Exosomal lncRNAs as diagnostic and therapeutic targets in multiple myeloma DOI Creative Commons
Hong Yan, Nan Jiang, M Kellis

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 14

Published: Jan. 16, 2025

Multiple Myeloma (MM) is the second most common malignancy of hematopoietic system, accounting for approximately 10% all hematological malignancies, and currently, there no complete cure. Existing research indicates that exosomal long non-coding RNAs (lncRNAs) play a crucial regulatory role in initiation progression tumors, involving various interactions such as lncRNA-miRNA, lncRNA-mRNA, lncRNA-RNA binding proteins (RBP). Despite significant clinical application potential lncRNAs, this area still faces challenges due to their low abundance technical limitations. To our knowledge, review first comprehensively integrate elucidate three mechanisms action lncRNAs MM, propose therapeutic targets cases based on these mechanisms. We highlight latest advancements biomarkers targets, offering not only comprehensive analysis MM but also new perspectives methods future diagnosis treatment multiple myeloma.

Language: Английский

Citations

1
Exploring ferroptosis and miRNAs: implications for cancer modulation and therapy DOI

Mobarakeh Ajam-Hosseini,

Sadegh Babashah

Molecular and Cellular Biochemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

Language: Английский

Citations

1
A review on the role of long non-coding RNA and microRNA network in clear cell renal cell carcinoma and its tumor microenvironment DOI Creative Commons
Qi Zhang,

Hao Ren,

Luqi Ge

et al.

Cancer Cell International, Journal Year: 2023, Volume and Issue: 23(1)

Published: Feb. 2, 2023

Renal cell carcinoma (RCC) is the second lethal urogenital malignancy with increasing incidence and mortality in world. Clear renal (ccRCC) one major subtype of RCC, which accounts for about 70 to 80% all RCC cases. Although many innovative therapeutic options have emerged during last few decades, efficacy these treatments ccRCC patients very limited. To date, prognosis advanced or metastatic still poor. The 5-year survival rate remains less than 10%, mainly attributes complexity heterogeneity tumor microenvironment (TME). It has been demonstrated that long non-coding RNAs (lncRNAs) perform an indispensable role initiation progression various tumors. They mostly function as sponges microRNAs (miRNAs) regulate expression target genes, finally influence growth, metastasis, apoptosis, drug resistance TME cells. However, lncRNA/miRNA/mRNA axis poorly understood. In this review, we summarized biological pathogenesis ccRCC, then discussed how TME, highlighted their potential application novel biomarkers targets ccRCC.

Language: Английский

Citations

18
Resistance of Lenvatinib in Hepatocellular Carcinoma DOI
Qiuran Xu, Dong‐Sheng Huang,

Jinhui Guo

et al.

Current Cancer Drug Targets, Journal Year: 2022, Volume and Issue: 22(11), P. 865 - 878

Published: April 30, 2022

Lenvatinib is a multikinase inhibitor which mainly hinders liver cancer proliferation by inhibiting angiogenesis. In 2018, was approved for the first-line treatment of patients with advanced hepatocellular carcinoma [HCC] in United States, European Union, Japan, and China. has been established as sorafenib replacement drug higher objective response rate [ORR], longer progression-free survival [PFS], time to progression [TTP]. resistance during become increasingly common recent years. Accordingly, it necessary determine factors associated explore solutions. this review, we sought mechanisms methods reduce summarized achievements treatment.

Language: Английский

Citations

28
Functional interplay between long non-coding RNAs and Breast CSCs DOI Creative Commons
Bashdar Mahmud Hussen, Ramiar Kamal Kheder,

Sara Tharwat Abdullah

et al.

Cancer Cell International, Journal Year: 2022, Volume and Issue: 22(1)

Published: July 21, 2022

Abstract Breast cancer (BC) represents aggressive affecting most women’s lives globally. Metastasis and recurrence are the two common factors in a breast patient's poor prognosis. Cancer stem cells (CSCs) tumor that able to self-renew differentiate, which is significant factor metastasis of cancer. Long non-coding RNAs (lncRNAs) describe group longer than 200 nucleotides do not have ability code for proteins. Some these lncRNAs can be mainly produced various tissues forms. In development spread malignancies, role influencing multiple signaling pathways positively or negatively, making them promise useful diagnostic prognostic markers treating disease guiding clinical therapy. However, it well known how interaction with CSCs will affect progression. Here, this review, we attempt summarize recent findings focus on cell self-renewal differentiation progression, as strategies challenges overcoming lncRNA's therapeutic resistance.

Language: Английский

Citations

17
Beyond the genome: lncRNAs as regulators of the PI3K/AKT pathway in lung cancer DOI Open Access
Waleed Hassan Almalki

Pathology - Research and Practice, Journal Year: 2023, Volume and Issue: 251, P. 154852 - 154852

Published: Oct. 4, 2023

Language: Английский

Citations

10
Uncovering the Regulatory Role of Long Non-Coding RNAs in Colorectal Cancer Progression and Liver Metastasis: Implications for Therapeutic and Diagnostic Targeting DOI Creative Commons

Mohammad Kavei,

Ahmad Hamta,

Ali Salari

et al.

Afghanistan Journal of Basic Medical Science, Journal Year: 2025, Volume and Issue: 2(1), P. 1 - 15

Published: Jan. 17, 2025

Background: Colorectal cancer (CRC) is a leading cause of cancer-related deaths, largely due to metastasis, particularly the liver, and limited understanding molecular mechanisms underlying this process. In study, we aimed investigate role long non-coding Methods: RNAs (lncRNAs) are key regulatory factors in CRC progression metastasis liver tissues. Using high-throughput sequencing microarray approaches, analyzed gene expression profiles from two independent lncRNA datasets identify potential players involved metastasis. Results: Our findings revealed five lncRNAs—PROX1-AS1, SOX9-AS1, LINC01594, LINC01555, APOA1-AS—previously known for their roles progression, now identified as being metastatic Additionally, 20 other lncRNAs, including VCAN-AS1, SYP-AS1, SMIM2-IT1, NCOA7-AS1, LINC01449, were also contributors Notably, lncRNAs—SATB2-AS1 LINC01116—emerged common candidates across both datasets, suggesting significant promoting liver. These lncRNAs hold promise targets therapeutic diagnostic development. Conclusion: study uncovers novel layer involving advance our behaviors that drive offer new avenues targeted strategies tools, CRC.

Language: Английский

Citations

0
The Dynamic Interplay between Melanoma Cells and CAFs: Implications Drug Resistance and Immune Evasion and Possible Therapeutics DOI
Chou‐Yi Hsu, Raed Obaid Saleh, Mohammed Sani Jaafaru

et al.

Experimental Cell Research, Journal Year: 2025, Volume and Issue: unknown, P. 114581 - 114581

Published: April 1, 2025

Language: Английский

Citations

0
Non‐coding RNA‐associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma DOI Creative Commons
Sattar Khashkhashi-Moghadam, Babak Bakhshinejad, Ali Khalafizadeh

et al.

Journal of Cellular and Molecular Medicine, Journal Year: 2021, Volume and Issue: 26(2), P. 287 - 305

Published: Dec. 14, 2021

Abstract Hepatocellular carcinoma (HCC), as the most prevalent liver malignancy, is annually diagnosed in more than half a million people worldwide. HCC strongly associated with hepatitis B and C viral infections well alcohol abuse. Obesity nonalcoholic fatty disease (NAFLD) also significantly enhance risk of cancer. Despite recent improvements therapeutic approaches, patients advanced stages show poor prognosis. Accumulating evidence provides support for regulatory role non‐coding RNAs (ncRNAs) There are variety reports indicating microRNAs (miRNAs) different HCC. Long (LncRNAs) exert their effects by sponging miRNAs controlling expression miRNA‐targeted genes. Circular (circRNAs) perform biological functions acting transcriptional regulators, miRNA sponges protein templates. Diverse studies have illustrated that dysregulation competing endogenous RNA networks (ceRNETs) remarkably correlated HCC‐causing diseases such chronic infections, steatohepatitis fibrosis/cirrhosis. The aim current article was to provide an overview molecular mechanisms underlying function ceRNETs modulate characteristics uncontrolled cell proliferation, resistance death, metabolic reprogramming, immune escape, angiogenesis metastasis. knowledge highlights potential these molecules novel diagnostic biomarkers targets

Language: Английский

Citations

23
Enhancer RNA (eRNA) in Human Diseases DOI Open Access
Yunzhe Wang, Chenyang Zhang, Yuxiang Wang

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(19), P. 11582 - 11582

Published: Sept. 30, 2022

Enhancer RNAs (eRNAs), a class of non-coding (ncRNAs) transcribed from enhancer regions, serve as type critical regulatory element in gene expression. There is increasing evidence demonstrating that the aberrant expression eRNAs can be broadly detected various human diseases. Some studies also revealed potential clinical utility these In this review, we summarized recent regarding pathological mechanisms well their across diseases, including cancers, neurodegenerative disorders, cardiovascular diseases and metabolic It could help us to understand how are engaged processes obtain better insight diagnosis, prognosis or therapy. The reviewed here indicate enormous therapeutic potency

Language: Английский

Citations

15